Article
Cobalt protoporphyrin pretreatment protects human embryonic stem cell-derived cardiomyocytes from hypoxia/reoxygenation injury in vitro and increases graft size and vascularization in vivo.
Stem cells translational medicine - 1 Jun 2014
Luo Jun, Weaver Matthew S, Cao Baohong, Dennis James E, Van Biber Benjamin, Laflamme Michael A, Allen Margaret D
Abstract excerpt
Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) can regenerate infarcted myocardium. However, when implanted into acutely infarcted hearts, few cells survive the first week postimplant. To improve early graft survival, hESC-CMs were pretreated with cobalt protoporphyrin (CoPP), a transcriptional activator of cytoprotective heme oxygenase-1 (HO-1). When hESC-CMs were challenged with an in vitro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.